Page last updated: 2024-12-06

cletoquine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cletoquine is a synthetic antimalarial drug that belongs to the 4-aminoquinoline class. It is structurally related to chloroquine, but with a modified side chain. Cletoquine has been studied for its potential efficacy against chloroquine-resistant malaria. Research has shown that it inhibits the growth of Plasmodium falciparum, the parasite responsible for malaria, by interfering with the heme detoxification pathway. Cletoquine has also shown promise in preclinical studies against other parasitic diseases, such as toxoplasmosis and leishmaniasis. Its synthesis involves a multi-step process, often starting with commercially available starting materials. The exact synthesis route and its details are generally proprietary information held by the research groups or companies involved in its development. Cletoquine is studied for its potential to overcome the challenges associated with chloroquine resistance, which has become a major public health issue in many malaria-endemic regions. Further research is needed to evaluate its safety and efficacy in human trials.'

Cross-References

ID SourceID
PubMed CID71826
CHEMBL ID580132
SCHEMBL ID1610518
MeSH IDM0141268

Synonyms (37)

Synonym
4298-15-1
cletochina [dcit]
2-[4-[(7-chloroquinolin-4-yl)amino]pentylamino]ethanol
desethylhydroxychloroquine
gnf-pf-1952 ,
CHEMBL580132
cletoquine
cletoquine [inn:ban]
83cvd213tu ,
cletoquinum [inn-latin]
cletoquina [inn-spanish]
cletoquinum
cletoquina
unii-83cvd213tu
cletochina
2-((4-((7-chloro-4-quinolyl)amino)pentyl)amino)ethanol
(+/-)-desethylhydroxychloroquine
hydroxychloroquine sulfate impurity c [ep impurity]
2-((4-((7-chloroquinolin-4-yl)amino)pentyl)amino)ethan-1-ol ,
cletoquine [inn]
SCHEMBL1610518
desethyl hydroxy chloroquine
AKOS028114494
ethanol, 2-[[4-[(7-chloro-4-quinolinyl)amino]pentyl]amino]-
2-(4-(7-chloroquinolin-4-ylamino)pentylamino)ethanol
FT-0701244
cletochina pound>>desethyl hydroxy chloroquine
BCP21024
2-((4-((7-chloroquinolin-4-yl)amino)pentyl)amino)ethanol
HY-135810
2-({4-[(7-chloroquinolin-4-yl)amino]pentyl}amino)ethan-1-ol
DTXSID70863361
Q27269423
CS-0114228
A934110
EX-A4281
2-[[4-[(7-chloro-4-quinolyl)amino]pentyl]amino]ethanol

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" There is a large degree of uncertainty in HCQ pharmacokinetic (PK) parameters which complicates dose selection when investigating its use in new disease states."( A linked physiologically based pharmacokinetic model for hydroxychloroquine and metabolite desethylhydroxychloroquine in SARS-CoV-2(-)/(+) populations.
Agrawal, V; Arnold, SLM; Barnabas, RV; Bershteyn, A; Chhonker, YS; Heller, KB; Johnston, C; Krows, ML; Landovitz, R; Laufer, M; Leingang, H; Murry, DJ; Paasche-Orlow, M; Stankiewicz Karita, HC; Steinbronn, C; Stewart, J; Wener, M, 2023
)
0.91

Bioavailability

ExcerptReferenceRelevance
" The orally bioavailable lead imidazolopiperazine confers complete causal prophylactic protection (15 milligrams/kilogram) in rodent models of malaria and shows potent in vivo blood-stage therapeutic activity."( Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
Barnes, SW; Bonamy, GM; Bopp, SE; Borboa, R; Bright, AT; Chatterjee, A; Che, J; Cohen, S; Dharia, NV; Diagana, TT; Fidock, DA; Froissard, P; Gagaring, K; Gettayacamin, M; Glynne, RJ; Gordon, P; Groessl, T; Kato, N; Kuhen, KL; Lee, MC; Mazier, D; McNamara, CW; Meister, S; Nagle, A; Nam, TG; Plouffe, DM; Richmond, W; Roland, J; Rottmann, M; Sattabongkot, J; Schultz, PG; Tuntland, T; Walker, JR; Winzeler, EA; Wu, T; Zhou, B; Zhou, Y, 2011
)
0.37

Dosage Studied

ExcerptRelevanceReference
"A dose-response relationship for hydroxychloroquine (HCQ), in terms of the proportion of patients achieving the Paulus 20% criteria for improvement, had previously been observed in patients with rheumatoid arthritis (RA) receiving a 6-week loading regimen of 400, 800, or 1,200 mg HCQ daily."( Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis.
Baethge, BA; Botstein, GR; Caldwell, J; Dietz, F; Ettlinger, R; Furst, DE; Gibbs, JP; Golden, HE; Lindsley, H; McLaughlin, GE; Moreland, LW; Munster, T; Roberts, WN; Rooney, TW; Rothschild, B; Sack, M; Sebba, AI; Shen, D; Weisman, M; Welch, KE; Yocum, D, 2002
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID449704NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID449706NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID449703NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay 2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID449705NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID602156Novartis GNF Liver Stage Dataset: Malariabox Annotation2011Science (New York, N.Y.), Dec-09, Volume: 334, Issue:6061
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (12.50)18.7374
1990's4 (25.00)18.2507
2000's3 (18.75)29.6817
2010's5 (31.25)24.3611
2020's2 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (6.25%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (93.75%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]